MTOB sodium_product_DataBase

Bioactivity	MTOB sodium is a potent C-terminal binding protein (CtBP) inhibitor. MTOB sodium attenuates repetitive head injury-elicited neurologic dysfunction and neuroinflammation via inhibition of the transactivation activity of CtBP1 and CtBP2. MTOB sodium antagonizes the transcriptional regulatory activity of CtBP1 and CtBP2 by eviction from their target promoters in breast cancer cell lines[1][2].
Target	CtBP
Invitro	MTOB sodium (10 mM) causes significant derepression (PE-cadherin/Vimentin ratio while reducing the pro-mesenchymal CD44/CD24 ratio, with a more significant trend (P<0.05) in MCF-7[2].
In Vivo	MTOB sodium (860 mg/kg; IP, at 1 h and 18 h after the first injury) effectively suppresses the increases duration of righting reflex, and significantly decreased neurological severity score (NSS) scores[1]. Animal Model:
Name	MTOB sodium
CAS	51828-97-8
Formula	C5H7NaO3S
Molar Mass	170.16
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Reference	[1]. Li H, et al. C-terminal binding proteins 1 and 2 in traumatic brain injury-induced inflammation and their inhibition as an approach for anti-inflammatory treatment. Int J Biol Sci. 2020 Feb 4;16(7):1107-1120. [2]. Di LJ, et al. Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nat Commun. 2013;4:1449.

PeptideDB